KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Operating Margin (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Operating Margin for 15 consecutive years, with 7.93% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin rose 2566.0% year-over-year to 7.93%, compared with a TTM value of 13.51% through Dec 2025, up 2137.0%, and an annual FY2025 reading of 13.51%, up 2137.0% over the prior year.
  • Operating Margin was 7.93% for Q4 2025 at Alnylam Pharmaceuticals, down from 29.46% in the prior quarter.
  • Across five years, Operating Margin topped out at 60.26% in Q1 2025 and bottomed at 104.89% in Q1 2021.
  • Average Operating Margin over 5 years is 35.36%, with a median of 36.7% recorded in 2023.
  • The sharpest move saw Operating Margin surged 12612bps in 2023, then crashed -4385bps in 2024.
  • Year by year, Operating Margin stood at 75.26% in 2021, then grew by 25bps to 56.3% in 2022, then skyrocketed by 53bps to 26.47% in 2023, then skyrocketed by 33bps to 17.73% in 2024, then soared by 145bps to 7.93% in 2025.
  • Business Quant data shows Operating Margin for ALNY at 7.93% in Q4 2025, 29.46% in Q3 2025, and 2.09% in Q2 2025.